Want to see GB:NFX full AI Analyst Report?
NFX Stock Chart & Stats
0.23 p
<0.01 p(2.11%)
At close: 4:00 PM EST
0.23 p
<0.01 p(2.11%)
Day’s Range― - ―
52-Week Range0.07 p - 0.56 p
Previous CloseN/A
Volume1.00M
Average Volume (3M)97.88M
Market Cap
£4.70M
Enterprise Value2.97M
Total Cash (Recent Filing)£930.28K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)6.0
Beta0.01
Next Earnings
Feb 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,609,750,000
10 Day Avg. Volume69,476,590
30 Day Avg. Volume97,880,797
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-6.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Debt-free Balance SheetThe absence of debt materially lowers solvency risk and preserves flexibility for financing or licensing negotiations. Over a 2–6 month horizon this structural low-leverage profile reduces near-term default risk and gives management optionality when raising capital or pursuing partnerships.
Proprietary Cocrystal Platform And Niche FocusOwning a cocrystal formulation platform and concentrating on fibrotic diseases are durable strategic assets: platform IP can enable differentiation, improved drug properties, and licensing opportunities. A focused therapeutic niche can streamline R&D and attract targeted collaborators or partners.
Narrowing Losses In 2025 Vs 2024A materially smaller loss in 2025 versus 2024 indicates improved cost discipline or resolution of one-offs. If sustained, lower structural losses prolong runway, reduce near-term financing frequency, and improve the company’s ability to execute development milestones over the medium term.
Bears Say
No Revenue; Stalled CommercializationThe company has generated no meaningful revenue for multiple years, signalling an absence of commercialized products. This undermines self-sustainability, increases reliance on external funding, and raises execution risk that the platform or assets will convert into recurring sales or licensing income.
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow indicates ongoing cash burn and dependency on external financing. Fluctuating but persistent outflows constrain strategic options, make timely milestone execution conditional on raises, and elevate dilution or financing risk over the coming months.
Shrinking Equity And Small Asset BaseDeclining equity and a reduced asset base leave a thin capital buffer against setbacks and limit collateral for debt or structured financing. This structural fragility increases vulnerability to adverse events and raises the bar for securing non-dilutive funding or large partnerships.
Nuformix Plc News
NFX FAQ
What was Nuformix Plc’s price range in the past 12 months?
Nuformix Plc lowest share price was 0.07 p and its highest was 0.56 p in the past 12 months.
What is Nuformix Plc’s market cap?
Nuformix Plc’s market cap is £4.70M.
When is Nuformix Plc’s upcoming earnings report date?
Nuformix Plc’s upcoming earnings report date is Feb 03, 2027 which is in 216 days.
How were Nuformix Plc’s earnings last quarter?
Nuformix Plc released its earnings results on May 28, 2026. The company reported 0 p earnings per share for the quarter, the consensus estimate of N/A by 0 p.
Is Nuformix Plc overvalued?
According to Wall Street analysts Nuformix Plc’s price is currently Overvalued.
Does Nuformix Plc pay dividends?
Nuformix Plc does not currently pay dividends.
What is Nuformix Plc’s EPS estimate?
Nuformix Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuformix Plc have?
Nuformix Plc has 2,609,750,000 shares outstanding.
What happened to Nuformix Plc’s price movement after its last earnings report?
Nuformix Plc reported an EPS of 0 p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -2.941%.
Which hedge fund is a major shareholder of Nuformix Plc?
Currently, no hedge funds are holding shares in GB:NFX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuformix Plc
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Technical Analysis
Evgen Pharma
―
Futura Medical
―
ImmuPharma
―
OptiBiotix Health
―
HemoGenyx Pharmaceuticals Plc
―